Alnwick, UK-based Contract Research and Development Organisation Arcinova has announced the award of a £1.5 million Innovate UK grant for the development of new flexible modular manufacturing technologies; a project which is set to demonstrate the operating feasibility of world first innovative continuous production tools.

The project, which will span a three-year period, will be undertaken in collaboration with a team led by Professor Mike George, with Professors Pete Licence and Sir Martyn Poliakoff at the University of Nottingham.

The aim of the project is to develop a continuous, flexible modular manufacturing technology platform which will enable Arcinova to handle increasingly complex chemistries with more discreet manufacturing steps.

The platform will be used in manufacturing operations where manufacturing inventories need to be kept low and product purity needs to be maximized, where manufacturing throughput and efficiency are maintained at a high level and equipment changeover can be rapidly facilitated to cope with low batch numbers.

Arcinova provides both integrated end to end solutions and standalone services to pharmaceutical and biotech companies.

The project outcome is set to position Arcinova as a world leader in defining continuous modular manufacturing technology for the support of new chemical entities (NCEs) development, scale up and manufacture.

The developed continuous modular manufacturing technology will be easily scalable, with a reduced manufacturing footprint when compared to more traditional, batch reactor approaches. The developed technologies will enable Arcinova to enhance manufacturing capacity and minimise inventories for highly reactive hazardous processes whereas for a batch process the reaction scale would be severely constrained.

Arcinova is a leading provider of drug substance process development and scale up support for a global client base and has inherited a site which has been operating for over 30 years with a wealth of process chemistry, safety, engineering and manufacturing support skills and infrastructure, both in batch and continuous manufacture.

The developed flexible modular manufacturing technology platform will enhance Arcinova’s existing infrastructure in GMP and non GMP assets, which include 5-litre and 20-litre GMP vessel streams, and build on its current capabilities in continuous processing technology.

Arcinova works across drug substance synthesis, drug product manufacture, Chemistry, Manufacturing and Control (CMC), bioanalytical and metabolism services, radiolabelling synthesis and synthesis of toxic/highly potent APIs. It also provides consultancy services and works in partnership with companies throughout the drug development process.

Ian Shott CBE, CEO of Arcinova said: “I have spent over 20 years championing the way that pharmaceuticals are manufactured in the UK and have been an enthusiastic advocate for new manufacturing technologies including continuous manufacturing and synthetic biology as enablers for new and radically different pharmaceutical production approaches.
“This focus on improving productivity is laid out in the 2017 whitepaper on UK Industrial Strategy. I was delighted to learn of our successful Innovate UK grant which will enable Arcinova to offer a compelling, innovative and simplified route to high grade pharmaceutical manufacture.”

Mike George, Professor of Chemistry at the University of Nottingham, said: “My colleagues and I at Nottingham are firmly convinced that flow chemistry can transform chemical manufacture in the UK and this partnership with Arcinova is an opportunity to turn our vision into reality.”

Launched in 2016, Arcinova operates from a 15,000m2 facility on a 34-acre site, which has benefited from decades of investment as a key research and development centre for Sanofi and Covance, allowing it to offer a unique range of complementary on-site capabilities as a Contract Research and Development Organisation (CRDO).

Arcinova’s senior scientific team are renowned for their world class, specialist research and development expertise and their big pharma and CRDO experience gives them extensive, broad ranging industry knowledge and insight.

Arcinova works with big pharma, specialty pharma and biotech companies across the globe, from established multinationals to emerging start-ups.


For media enquiries, please contact Richard Holmes on 0345 075 5955 / 07538 055392 or email

Notes to editors
Launched in 2016, Arcinova operates from a 15,000m2 facility on a 34-acre site in Alnwick, Northumberland, UK. The world-class facility has benefited from more than 34 years of investment as a key research and development centre for Sanofi and Covance.
Arcinova serves the global pharmaceutical and biotechnology communities and helps companies to develop medicines and take them to market quickly and effectively.

The company offers a high degree of expertise and capabilities in drug substance synthesis, drug product manufacture, CMC, Bioanalytical and Metabolism services, radiolabelling synthesis and synthesis of toxic/highly potent APIs, and can provide both integrated solutions and standalone services.
Arcinova’s services are operated to GLP, GCP and GMP requirements and its team has high level, big pharma experience, which, combined with the company’s expertise as a CRDO, gives Arcinova extensive, broad ranging industry knowledge.
For more information, visit